Fiche publication
Date publication
octobre 2022
Journal
Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc
,
Pr NERICH Virginie
,
Dr HERVIEU Alice
,
Dr CHARON-BARRA Céline
Tous les auteurs :
Chaigneau L, Jary M, Nerich V, Hervieu A, Aubry S, Charon Barra C, Meynard G, Neumann F, Kalbacher E, Isambert N
Lien Pubmed
Résumé
Soft tissue sarcomas (STS) are a rare and heterogenous group of tumors, with poor prognostic, judging from their frequency to relapse. Few drugs are available after the conventional first line regimen. Since 2007, trabectedin got approval after failure of anthracyclines and ifosfamide, for advanced or metastatic STS. This led to a FDA approval in 2015, but real-world evidence are still required, complementary to the pivotal phase II and III trials.
Référence
Oncology. 2022 10 25;:
